Hydroxyzine and Metabolites as a Source of Interference in Carbamazepine Particle-Enhanced Turbidimetric Inhibition Immunoassay (PETINIA)

A 32-year-old epileptic patient with a lengthy history of multiple-drug abuse and psychotic disorders was found to have an elevated serum carbamazepine concentration of 40.5 mg/L (therapeutic range 4-12 mg/L) using particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Serum reanalysis by LC-DAD revealed only high hydroxyzine (HDZ) concentration (HDZ = 0.55 mg/L; therapeutic range <0.1 mg/L), suggesting cross-reactivity between HDZ and PETINIA. To confirm this hypothesis, the authors tested 2 commercially available carbamazepine immunoassays, PETINIA and EMIT 2000, for in vitro cross-reactivity with HDZ and 2 HDZ metabolites (cetirizine and norchlorcyclizine). To determine the frequency of this interaction in a clinical setting, 40 sera of 39 patients taking HDZ without carbamazepine were tested by both immunoassays. For some samples, LC-ESI-MS analysis of HDZ metabolites was performed. Additionally, cross-reactivities produced by other benzhydrylpiperazine drugs were evaluated. in vitro, 5 mg of HDZ, cetirizine, and norchlorcyclizine cross-reacted with PETINIA at 85%, 125%, and 66%, respectively. Conversely, EMIT 2000 showed no cross-reactivity. For PETINIA, erroneous carbamazepine concentrations were detected in 35 out of 40 sera of patients taking HDZ. The magnitude of interference correlated moderately with serum HDZ concentrations (Spearman ρ coefficient 0.58, P < 0.001), suggesting a major role for the multiple HDZ metabolites (4 serum metabolites were detected by LC-ESI-MS). Furthermore, other benzhydrylpiperazine drugs (eg, oxatomide) showed in vitro cross-reactivity with PETINIA. In conclusion, HDZ and its metabolites cross-react with carbamazepine PETINIA immunoassay, which could significantly affect the correct interpretation of serum carbamazepine concentrations in patients treated with HDZ.

[1]  S. Schmidt,et al.  Signs and symptoms of carbamazepine overdose , 1995, Journal of Neurology.

[2]  F. Parant,et al.  Cross-Reactivity Assessment of Carbamazepine-10,11-epoxide, Oxcarbazepine, and 10-Hydroxy-Carbazepine in Two Automated Carbamazepine Immunoassays: PETINIA and EMIT 2000 , 2003, Therapeutic drug monitoring.

[3]  Brian L. Smith,et al.  Primary standardization of assays for anticonvulsant drugs: comparison of accuracy and precision. , 2002, Clinical chemistry.

[4]  G. Joubert,et al.  Premedication from a patient perspective--morphine, midazolam, hydroxyzine and placebo compared. , 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[5]  P. Watkins,et al.  Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans , 2002, Clinical pharmacology and therapeutics.

[6]  F. Simons.  H1-antihistamines in children. , 2002, Clinical allergy and immunology.

[7]  S. Soldin,et al.  Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. , 2001, Clinical biochemistry.

[8]  H. Girault,et al.  Ionic Partition Diagram of the Zwitterionic Antihistamine Cetirizine , 2001 .

[9]  I. Watson,et al.  An audit of therapeutic drug monitoring service provision by laboratories participating in an external quality assessment scheme. , 1998, Therapeutic drug monitoring.

[10]  R. Flanagan.  Guidelines for the Interpretation of Analytical Toxicology Results and Unit of Measurement Conversion Factors , 1998, Annals of clinical biochemistry.

[11]  J. Touchon,et al.  [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo]. , 1997, L'Encephale.

[12]  P. Kintz,et al.  Gas chromatographic identification and quantification of hydroxyzine: application in a fatal self-poisoning. , 1990, Forensic science international.

[13]  T. Tomson,et al.  Carbamazepine-10,11-epoxide in epilepsy. A pilot study. , 1990, Archives of neurology.

[14]  F. Simons,et al.  The Pharmacokinetics and Pharmacodynamics of Hydroxyzine in Patients with Primary Biliary Cirrhosis , 1989, Journal of clinical pharmacology.

[15]  M. Holmes,et al.  Carbamazepine and its epoxide: Relation of plasma levels to toxicity and seizure control , 1989, Annals of neurology.

[16]  F. Simons,et al.  Pharmacokinetic and pharmacodynamic studies of the H1‐receptor antagonist hydroxyzine in the elderly , 1989, Clinical pharmacology and therapeutics.

[17]  L. F. Chasseaud,et al.  The metabolism and pharmacokinetics of 14C-cetirizine in humans. , 1987, Annals of allergy.

[18]  K. Hara,et al.  Changed compounds of hydroxyzine in a human urine. , 1986, Forensic science international.

[19]  T. Tomson,et al.  Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide , 1986 .

[20]  V. Spiehler,et al.  Another fatal case involving hydroxyzine. , 1984, Journal of analytical toxicology.

[21]  G. R. Johnson.  A fatal case involving hydroxyzine. , 1982, Journal of analytical toxicology.

[22]  J. Heykants,et al.  Steady-state plasma levels of flunarizine in chronically treated patients. , 1979, Arzneimittel-Forschung.

[23]  S F Pong,et al.  Comparative studies on distribution, excretion, and metabolism of hydroxyzine-3H and its methiodide-14C in rats. , 1974, Journal of pharmaceutical sciences.